The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...
- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...
- Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for ...
BridgeBio's pipeline assets like encaleret and BBP-418 offer optionality but lack near-term cash flow and face regulatory ...
1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval, indicating strong initial market uptake. Attruby™ is the first and only near-complete ...
The cost of Attruby can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Attruby. As with all medications, ...
BridgeBio Pharma Inc. will report fourth-quarter and full-year 2025 results after the market closes on Tuesday, February 24, a closely watched print for a rare-disease developer seeking to prove its ...
On 12 February 2026, BridgeBio Pharma reported positive topline Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia, showing statistically significant gains in annualized ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that can lead to the heart not pumping well. attruby (acoramidis) was approved in 2024 by the FDA to treat people with ATTR-CM. It has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results